17.81
price up icon8.00%   1.32
after-market Dopo l'orario di chiusura: 17.46 -0.35 -1.97%
loading
Precedente Chiudi:
$16.49
Aprire:
$17.68
Volume 24 ore:
138.01K
Relative Volume:
0.25
Capitalizzazione di mercato:
$1.07B
Reddito:
$1.23M
Utile/perdita netta:
$-214.90M
Rapporto P/E:
-4.3205
EPS:
-4.1222
Flusso di cassa netto:
$-151.25M
1 W Prestazione:
+9.94%
1M Prestazione:
+21.32%
6M Prestazione:
-18.34%
1 anno Prestazione:
-44.05%
Intervallo 1D:
Value
$17.62
$18.03
Intervallo di 1 settimana:
Value
$16.08
$18.03
Portata 52W:
Value
$10.91
$40.26

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
Nome
Spyre Therapeutics Inc
Name
Telefono
(617) 651-5940
Name
Indirizzo
221 CRESCENT STREET, WALTHAM
Name
Dipendente
65
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SYRE's Discussions on Twitter

Confronta SYRE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SYRE
Spyre Therapeutics Inc
17.81 995.23M 1.23M -214.90M -151.25M -4.1222
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-08 Iniziato Leerink Partners Outperform
2025-03-18 Iniziato Wolfe Research Outperform
2024-09-04 Iniziato Wedbush Outperform
2024-07-16 Iniziato Evercore ISI Outperform
2024-05-02 Iniziato Robert W. Baird Outperform
2024-03-01 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-20 Iniziato BTIG Research Buy
2023-12-11 Iniziato Guggenheim Buy
2023-12-11 Iniziato Jefferies Buy
2020-05-04 Iniziato Piper Sandler Overweight
2019-03-21 Iniziato JP Morgan Overweight
2018-09-04 Downgrade Wells Fargo Outperform → Market Perform
2018-04-24 Iniziato Evercore ISI Outperform
2018-03-14 Reiterato Needham Buy
Mostra tutto

Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie

pulisher
Jul 23, 2025

Spyre Therapeutics Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Spyre Therapeutics Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Spyre Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Spyre Therapeutics Inc. stock priceFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $53.40 - Defense World

Jul 20, 2025
pulisher
Jul 16, 2025

Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How Spyre Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Spyre Therapeutics Inc. stock price move sharplyPotential Rocket List - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation - Yahoo Finance

Jul 15, 2025
pulisher
Jul 03, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - TradingView

Jul 03, 2025
pulisher
Jun 26, 2025

GAMMA Investing LLC Purchases New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 26, 2025
pulisher
Jun 23, 2025

Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE) - The Globe and Mail

Jun 23, 2025
pulisher
Jun 18, 2025

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 16, 2025
pulisher
Jun 11, 2025

California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada

Jun 03, 2025

Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):